Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic sequencing using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.

Number of Participants with Adverse Events as a Measure of Safety

Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.

MTD of palbociclib isethionate defined as the highest dose level at which six patients have been treated with at most one patient experiencing a dose limiting toxicity and the next higher dose level has been determined to be too toxic

Incidence of adverse events

Objective responses (partial response + complete response)

(and 2 more...)

55

All

4 Years to 21 Years (Child, Adult)

NCT02255461

PBTC-042U01CA081457

October 2014

December 31, 2018

December 31, 2018

October 2, 2014

September 28, 2017

Childrens Hospital Los AngelesLos Angeles, California, United States

Lucile Packard Children Hospital Stanford UniversityPalo Alto, California, United States

Childrens National Medical CenterWashington, D.C., District of Columbia, United States